Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

130
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
130
Serum Laboratory Studies, Stool Test, Breath Test01:30

Serum Laboratory Studies, Stool Test, Breath Test

670
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
670

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort study.

Journal of hepatology·2026
Same author

The 2024 International Liver Transplant Society and International Liver Cancer Association Consensus Recommendations for Liver Transplantation for Liver Cancer.

Liver cancer·2026
Same author

Response to Muhammad Uwais Ashra, et al.

Journal of hepatology·2026
Same author

Response to İlgin Özden and Kocheise, et al.

Journal of hepatology·2026
Same author

Imaging-Based Liver Transplant Eligibility in Hepatocellular Carcinoma: Analysis of 1,094 Patients Using Liver Imaging Reporting and Data System and Asia-Pacific Guideline-Based Criteria.

Liver cancer·2026
Same author

Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma.

JHEP reports : innovation in hepatology·2026

Related Experiment Video

Updated: Dec 28, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.8K

Biomarkers for Hepatobiliary Cancers.

Jean-Charles Nault1,2,3, Augusto Villanueva4,5

  • 1Centre de Recherche des Cordeliers, Functional Genomics of Solid Tumors Laboratory, Sorbonne Université, Inserm, USPC, Université Paris Descartes, Université Paris Diderot, Université Paris 13, Paris, France.

Hepatology (Baltimore, Md.)
|February 12, 2020
PubMed
Summary

Systemic therapies have improved survival for advanced liver cancers like hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Biomarker development is crucial for better diagnosis, prognosis, and treatment response prediction in these challenging diseases.

More Related Videos

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

570
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.0K

Related Experiment Videos

Last Updated: Dec 28, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.8K
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

570
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Translational Medicine

Background:

  • Clinical management of liver cancers, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), has evolved with new systemic therapies.
  • While survival has improved, particularly in advanced stages, outcomes remain poor, necessitating further advancements.
  • Biomarkers are critical for enhancing diagnosis, prognosis, and predicting treatment response, aiding patient stratification.

Purpose of the Study:

  • To summarize the current status of biomarker development for HCC and CCA.
  • To highlight the challenges and progress in translating molecular understanding into clinical biomarkers for liver cancers.

Main Methods:

  • Review of recent advances in understanding molecular alterations in HCC and CCA.
  • Analysis of the identification of therapeutic targets and ongoing clinical trials for biomarker-driven therapies in CCA.
  • Assessment of the reasons for the lack of biomarker translation in HCC.

Main Results:

  • Systemic therapies, including immune-based and biomarker-driven approaches, have improved survival in advanced HCC and CCA.
  • Several therapeutic targets have been identified in CCA, with biomarker-driven therapies in phase 2/3 trials.
  • Limited progress in translating molecular insights into biomarkers for HCC due to lack of druggable mutations and disease heterogeneity.

Conclusions:

  • Biomarker development is essential for improving patient stratification and maximizing clinical benefits in liver cancer management.
  • While CCA shows promise with identified targets and ongoing trials, HCC faces challenges in biomarker discovery.
  • Continued research into molecular alterations and biomarker validation is crucial for advancing liver cancer treatment.